Substituted fused heterocyclic compounds of the formula (I) and pharmacologically acceptable salts thereof:
wherein R1 is a group of the formula (II) or (III):
R4 is a substituted phenyl or a pyridyl which may have a substituent. R5 is hydrogen or the like. R6 is hydrogen, a C1-6 alkyl group or the like. D is oxygen or sulfur. E is a CH group or nitrogen. R2 is hydrogen or the like. R3 is a 2,4-dioxothiazolidin-5-ylmethyl group or the like. A is a C1-6 alkylene group. B is oxygen or sulfur. These compounds and salts are useful as the active ingredient of pharmaceutical compositions which can be used to treat patients because these compounds and salts have excellent insulin-resistance improving action, lipid-peroxide-production inhibitory action, 5-lipoxygenase inhibitory action and the like.
式(I)的取代融合
杂环化合物及其药学上可接受的盐:
其中R1是式(II)或(III)的基团:
R4是取代苯基或可能有取代基的
吡啶基。R5是氢或类似物。R6是氢、C1-6烷基或类似物。D是氧或
硫。E是CH基团或氮。R2是氢或类似物。R3是2,4-二氧代
噻唑啉-5-基甲基基团或类似物。A是C1-6烷基基团。B是氧或
硫。这些化合物和盐可用作药物组合物的活性成分,可用于治疗患者,因为这些化合物和盐具有出色的改善
胰岛素抵抗作用、抑制脂质过氧化产物生成作用、5-脂氧合酶抑制作用等。